Campaigning & Advocacy

As a charity we are actively involved in campaigning on behalf of patients and their carers, which we feel is an important part of the work that we do. We are passionate about doing everything we can to improve the experience of patients throughout their cancer journey.

Our campaigns

We run campaigns throughout the year, and need you to get involved and help raise awareness.

What is campaigning and advocacy?

As a charity we are actively involved in campaigning on behalf of patients and their carers, which we feel is an important part of the work that we do. We are passionate about doing everything we can to improve the experience of patients throughout their cancer journey.

Know your rights toolkit

We have produced a number of bitesize pieces of information to help you understand the options that are available to you, access further information and make informed decisions.

Patient Advocacy Groups

We are involved with a number of organisations and coalitions on your behalf which, through collaborative working, aim to ensure that the collective voice of blood cancer patients is heard.

Working with the pharmaceutical industry

We work with the pharmaceutical industry to ensure that they take the interests of patients into account when developing new drugs and treatments for blood cancer patients.

Health Technology Appraisals

This involves working with bodies such as the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) to ensure that the views of patients are taken into account when making decisions over access to drugs and treatments.

Living well with Leukaemia

It's important to look after yourself, your body and your mind following a diagnosis of a blood cancer.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

April 23rd

Cost of leukaemia – Tony Pullen on sick pay

Tony Pullen talks openly about how being diagnosed with hairy cell leukaemia (HCL) has impacted his financial stability. ...

April 11th

Approval for the first CAR-T treatment for ALL is renewed

CAR-T therapy, tisagenlecleucel, has been given long term approval to be used on the NHS in England, thanks to a decision made by the National Institute for Health and Care Excellence's (NICE). ...

March 11th

NEW oral treatment for AML patients approved in Scotland

Leukaemia Care are pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patient with an IDH1 mutation who are ineligible for standard induction chemotherapy now have access to ivosidenib with azacitidine thanks to the decision made by the Scottish Medicines Consortium (SMC) today....